Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ensysce Biosciences Inc (NQ: ENSC )

0.5250 +0.0249 (+4.98%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jun 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ensysce Biosciences Inc

< Previous 1 2 3 4 Next >
Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program
Via ACCESSWIRE
Ensysce Biosciences to Participate in the EPHMRA 2024 Annual Meeting
Via ACCESSWIRE
Ensysce Biosciences Regains Compliance with Nasdaq
Via ACCESSWIRE
Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform
Via ACCESSWIRE
Ensysce Biosciences Reports First Quarter 2024 Financial Results
Via ACCESSWIRE
Ensysce Biosciences’ CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge Magazine
Via ACCESSWIRE
Ensysce Biosciences' Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published
Via ACCESSWIRE
Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results
Via ACCESSWIRE
Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection
Via ACCESSWIRE
Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript
Via ACCESSWIRE
Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
Via ACCESSWIRE
Ensysce Biosciences Receives Positive Nasdaq Listing Determination
Via ACCESSWIRE
Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds
Via ACCESSWIRE
Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual Conference
Via ACCESSWIRE
Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain
Via ACCESSWIRE
Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPAR
Via ACCESSWIRE
Ensysce Biosciences Announces Key Efficacy Data for Lead Analgesic
Via ACCESSWIRE
Ensysce Biosciences Announces Completion of $1.7 Million Convertible Note Financing
Via ACCESSWIRE
Ensysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL Meeting
Via ACCESSWIRE
Ensysce Biosciences Issues 2024 Shareholder Letter
Via ACCESSWIRE
Ensysce Biosciences Postpones Special Meeting of Stockholders to December 29, 2023
Via ACCESSWIRE
Ensysce Biosciences Discusses TAAP and MPAR(R) Applications and OncoZenge Partnership with The Stock Day Podcast
Via ACCESSWIRE
Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-development of BupiZenge(TM) in the United States
Via ACCESSWIRE
Ensysce Biosciences Announces Enrollment Completion for PF614-201 Clinical Study
Via ACCESSWIRE
Ensysce Biosciences Reports Third Quarter 2023 Financial Results
Via ACCESSWIRE
Ensysce Biosciences Secures $1.7 Million Convertible Note Financing
Via ACCESSWIRE
Ensysce Biosciences Announces Poster Presentation at the AAPS 2023 PharmSci 360
Via ACCESSWIRE
Ensysce Biosciences Releases "Highlights Video" of PAINWeek 2023 Symposium
Via ACCESSWIRE
Ensysce Biosciences to Chair the Fierce New Product Planning Summit 2023
Via ACCESSWIRE
Ensysce Biosciences Announces Completion of Site Initiation Visit for PF614-201 Clinical Study
Via ACCESSWIRE
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.